Clinicians at the Fatty Liver Clinic at Massachusetts General Hospital diagnose, treat and monitor patients with fatty liver disease.

Dan Pratt, MD and Kathleen Corey, MD, MPH  

Fatty Liver Clinic: Clinical Trials

The MGH Liver Clinic currently has several studies to monitor the progress of patients with fatty liver disease.

It remains unknown why some people develop fatty liver, and why some develop advanced disease while others do not. The Non-Alcoholic Fatty Liver Disease Repository follows patients every 6 months when they come for their regularly scheduled appointments and monitors their liver disease and response to treatment.

Additional ongoing clinical trials include the ARISE (Acid Lipase Replacement Investigating Safety and Efficacy) study, which will evaluate the safety and efficacy of sebelipase alfa (SBC-102, recombinant human LAL) administered every other week as an intravenous infusion in patients with late onset lysosomal acid lipase deficiency (LALD). LALD is a genetic disease characterized by abnormal fat accumulation in many parts of the body due to a decrease in activity of the enzyme lysosomal acid lipase (LAL). The late onset form of the disease occurs in children and adults and can cause cirrhosis and dyslipidemia. Late onset LALD is characterized by an enlarged liver, abnormal liver function tests (LFTs) and elevated cholesterol levels. Patients diagnosed with suspected LALD can be screened at the MGH Fatty Liver Clinic. Those with LALD may be eligible for enrollment.

 

 

Ongoing clinical trials for non-alcoholic steatohepatitis: Actively recruiting


Condition:

Non-alcoholic steatohepatitis

Study title:

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Description of study:

The goal of this study is to see if the monoclonal antibody, GS-6624 is effective at preventing the progression of liver fibrosis in people with NASH.

Basic eligibility criteria:

Adults aged 18-65 with NASH; willing to commit to a 2 year study with visits twice a month. Clinical Trials.gov identifier: NCT01672866

Principal Investigator:

Kathleen Corey, MD, MPH

Contact:

Jenna Gustafson: 617-724-3836 and Kyle Malecki: 617-726-3670


Condition:

Non-alcoholic steatohepatitis

Study title:

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Description of study:

The goal of this study is to see if the monoclonal antibody, GS-6624 is effective at reversing liver scarring and heal cirrhosis in people with NASH.

Basic eligibility criteria:

Adults aged 18-65 with NASH and cirrhosis; willing to commit to a 2 year study with visits twice a month; Clinical Trials.gov identifier: NCT01672879

Principal Investigator:

Kathleen Corey, MD, MPH

Contact:

Jenna Gustafson: 617-724-3836 and Kyle Malecki: 617-726-3670